SphynKx Therapeutics Receives $50K Investment from CIT GAP Funds

SphynKx Therapeutics LLC, a Charlottesville, Va.-based biotechnology company, has received a $50k investment from CIT GAP Funds.

SphynKx intends to use the funding to conduct further research.

Co-founded by President, CEO Andrew Bolt, CSO Kevin Lynch, Ph.D., Vice President, Drug Discovery Timothy Macdonald, Ph.D., and Vice President, Medicinal Chemistry Webster Santos, Ph.D., the company focuses on the discovery and development of small molecule therapeutics that target the sphingosine 1-phosphate (S1P) pathway in novel ways, potentially leading to innovative treatments for diseases such as fibrosis and cancer.



Join the discussion